Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination With Systemic Anti-Cancer Therapies in Subjects With Advanced Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1/1b Open-label, Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination With Systemic Anti-Cancer Therapies in Subjects With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amezalpat (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Leiomyosarcoma; Liposarcoma; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors Tempest Therapeutics

    • Most Recent Events

    • 04 Apr 2024 Results presented in a Tempest Therapeutics Media Release.
    • 04 Apr 2024 According to a Tempest Therapeutics media release, positive clinical data from the dose-escalation portion was published in Journal of Cancer Research Communications.
    • 27 Jan 2024 Results assessing Pharmacodynamics and gene expression analysis of patients with renal cell carcinoma treated with combination nivolumab and TPST-1120 presented at the 2024 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top